Overview

Imatinib in Acute Ischaemic Stroke

Status:
Recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

A clinical trial comparing treatment with Imatinib to placebo when administered within 8 hours of stroke onset for 6 days, in addition to conventional stroke treatment after acute ischaemic stroke.

Phase:

Phase 3

Details

Lead Sponsor:

Niaz Ahmed

Treatments:

Imatinib Mesylate